



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bandaru, et al EXAMINER: Not Yet Assigned
SERIAL NUMBER: 10/691,165 ART UNIT: Not Yet Assigned
FILING: DATE: October 21, 2003
FOR: Novel Polypeptides and Polynucleotides Encoding Same

Mail Stop IDS
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:


1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages) in duplicate;
3. No Copies of Cited reference A1-A19
4. Copies of Cited references C1-C7 and;
5. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any additional fees that may be due to Deposit Account No.502648, Reference No. Cura 85 CON1 (15966-585 CON1). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 203/974-6303, New Haven, Connecticut.

Respectfully submitted,

Date: March 25, 2004


George Yahwak, Reg. No. 26,824
c/o Curagen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303
Fax: (203) 401-3351



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Bandaru, et al. EXAMINER: Not Yet Assigned
SERIAL NUMBER: 10/691,165 ART UNIT: Not Yet Assigned
FILING DATE: October 21, 2003
FOR: Novel Polypeptides and Polynucleotides Encoding Same

Mail Stop IDS
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. § 1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs, the enclosed form PTO-1449 to evidence that the cited information has been fully considered by Patent and Trademark Office during the examination of this application.


By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is

considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited in the Statement is, or considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statement by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 502648, Reference No. Cura 85 CON1 (15966-585 CON1).

Respectfully submitted,

Date: March 25, 2004



George Yahwak, Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303
Fax: (203) 401-3351

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/691,165
	Filing Date	10/21/03
	First Named Inventor	Bandaru, et al.
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	Cura 85 Con1

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,522,811	06/11/85	Eppstein, et al.	514	2	07/08/1982
	A2	4,683,195	07/28/87	Mullis, et al.	435	6	02/07/1986
	A3	4,683,202	07/28/87	Kary B. Mullis	435	91	10/25/1985
	A4	4,736,866	04/12/88	Leder, et al.	800	1	06/22/1984
	A5	4,816,567	03/28/89	Cabilly, et al.	530	387	04/08/1983
	A6	4,870,009	09/26/89	Evans, et al.	435	70	12/15/1983
	A7	4,873,191	10/10/89	Wagner, et al.	435	172.3	08/18/1986
	A8	4,873,316	10/10/89	Meade, et al.	530	412	06/23/1987
	A9	4,946,778	08/07/90	Ladner, et al.	435	69.6	01/19/1989
	A10	4,987,071	01/22/91	Cech, et al.	435	91	12/03/1986
	A11	5,116,742	05/26/92	Cech, et al.	435	91	03/24/1989
	A12	5,223,409	06/29/93	Ladner, et al.	435	69.7	03/01/1991
	A13	5,225,539	07/06/93	Gregory P. Winter	530	387.3	10/25/1991
	A14	5,233,409	08/03/93	Karl W. Schwab	356	402	02/25/1992
	A15	5,272,057	12/21/93	Smuison, et al.	435	6	10/14/1988
	A16	5,283,317	02/01/94	Siafer, et al.	528	405	10/11/1991
	A17	5,328,470	07/12/94	Nabel, et al.	601	101	07/26/1991
	A18	5,459,039	10/17/95	Modrich, et al.	435	6	03/18/1994
	A19	5,493,531	02/20/96	Pascucci, et al.	365	200	12/07/1994

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Protein Accession Number: AAA36746 (03-AUG-1993).

Date of Deposit: March 25, 2004

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C2	Nucleotide Accession Number: AL109798 (11-DEC-2001).
	C3	Protein Accession Number: CAB81612 (27-SEP-2000).
	C4	Protein Accession Number: NP_031965 (24-DEC-2003).
	C5	Protein Accession Number: NP_037412 (23-DEC-2003).
	C6	Protein Accession Number: NP_065387 (21-DEC-2003).
	C7	Protein Accession Number: O97428 (CAA21832) (22-JAN-1999).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.